Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-24 Mln
ROE
-10.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
-0.8
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
54,515,600
CFO
$-97.82 Mln
EBITDA
$-76.42 Mln
Net Profit
$-123.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Better Therapeutics Inc (BTTX)
| -- | -- | -- | -99.9 | -97.0 | -- | -- |
|
BSE Sensex*
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Better Therapeutics Inc (BTTX)
| -82.4 | -76.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Better Therapeutics Inc (BTTX)
|
0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 |
| 0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 | |
| 39.5 | 7,353.6 | 0.0 | -697.5 | -- | -38.3 | -- | 3.6 |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform... to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California. Read more
Co-Founder & Executive Chairman
Mr. David P. Perry M.B.A.
Co-Founder & Executive Chairman
Mr. David P. Perry M.B.A.
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Better Therapeutics Inc (BTTX) stood at $ 24 Mln as on 30-Sep-23
The share price of Better Therapeutics Inc (BTTX) is $0.00 (NASDAQ) as of 29-Jan-2025 15:00 EDT. Better Therapeutics Inc (BTTX) has given a return of -96.97% in the last 3 years.
Better Therapeutics Inc (BTTX) has a market capitalisation of $ 0 Mln as on 29-Jan-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Better Therapeutics Inc (BTTX) is 2.29 times as on 29-Jan-2025, a 4% premium to its peers’ median range of 2.21 times.
Since, TTM earnings of Better Therapeutics Inc (BTTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Better Therapeutics Inc (BTTX) and enter the required number of quantities and click on buy to purchase the shares of Better Therapeutics Inc (BTTX).
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
The CEO & director of Mr. David P. Perry M.B.A.. is Better Therapeutics Inc (BTTX), and CFO & Sr. VP is Mr. David P. Perry M.B.A..
There is no promoter pledging in Better Therapeutics Inc (BTTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
701
|
|
|
2
|
|
|
0
|
|
|
701
|
|
|
2
|
|
|
0
|
| Better Therapeutics Inc (BTTX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Better Therapeutics Inc (BTTX) was $-24 Mln.
$-0.01
(
